Pharmacology of polymyxins: new insights into an 'old'class of antibiotics
Increasing antibiotic resistance in Gram-negative bacteria, particularly in Pseudomonas
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global …
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global …
Carbapenemase-producing enterobacteriaceae
Y Doi, DL Paterson - Seminars in respiratory and critical care …, 2015 - thieme-connect.com
Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the
1990s, but are today encountered routinely in hospitals and other healthcare facilities in …
1990s, but are today encountered routinely in hospitals and other healthcare facilities in …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki… - … : The Journal of …, 2019 - Wiley Online Library
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens
AM Sandri, CB Landersdorfer, J Jacob… - Clinical infectious …, 2013 - academic.oup.com
Background. Polymyxin B is a last-line therapy for multidrug-resistant gram-negative
bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients …
bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients …
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy
Pseudomonas aeruginosa and Acinetobacter baumannii are major nosocomial pathogens
worldwide. Both are intrinsically resistant to many drugs and are able to become resistant to …
worldwide. Both are intrinsically resistant to many drugs and are able to become resistant to …
Pharmacokinetics and pharmacodynamics of 'old'polymyxins: what is new?
'Old'colistin and polymyxin B are increasingly used as last-line therapy against multidrug-
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …
Pharmacokinetics of intravenous polymyxin B in critically ill patients
AP Zavascki, LZ Goldani, G Cao… - Clinical infectious …, 2008 - academic.oup.com
Background. Although not much pharmacokinetic knowledge is available, polymyxin B is
increasingly used for treatment of infections caused by gram-negative bacteria that are …
increasingly used for treatment of infections caused by gram-negative bacteria that are …
Combination therapy for carbapenem-resistant Gram-negative bacteria
AP Zavascki, JB Bulitta… - Expert review of anti …, 2013 - Taylor & Francis
The emergence of resistant to carbapenems Gram-negative bacteria (CR GNB) has severely
challenged antimicrobial therapy. Many CR GNB isolates are only susceptible to …
challenged antimicrobial therapy. Many CR GNB isolates are only susceptible to …
A review of the clinical pharmacokinetics of polymyxin B
Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer
therapies are becoming available, it is anticipated that resistance to these agents will …
therapies are becoming available, it is anticipated that resistance to these agents will …